A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity

Nature

Volumn 503, Issue 7477, 2013, Pages 493-499

  Okada Iwabu, Miki ^a,b   Yamauchi, Toshimasa ^a,b   Iwabu, Masato ^a,b   Honma, Teruki ^c   Hamagami, Ken Ichi ^a   Matsuda, Koichi ^a   Yamaguchi, Mamiko ^a   Tanabe, Hiroaki ^c   Kimura Someya, Tomomi ^c   Shirouzu, Mikako ^c   Ogata, Hitomi ^d   Tokuyama, Kumpei ^d   Ueki, Kohjiro ^a   Nagano, Tetsuo ^b   Tanaka, Akiko ^b,c   Yokoyama, Shigeyuki ^b,c   Kadowaki, Takashi ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c RIKEN   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; ADIPONECTIN RECEPTOR AGONIST; ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; UNCLASSIFIED DRUG;

DIABETES; MOLECULAR ANALYSIS; MUSCLE; OBESITY; RODENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG IDENTIFICATION; DRUG STRUCTURE; GLUCOSE INTOLERANCE; IN VITRO STUDY; INSULIN RESISTANCE; KNOCKOUT GENE; LIFESPAN; LIPID DIET; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL;

ADENYLATE KINASE; ADIPONECTIN; ADIPOSE TISSUE, WHITE; ADMINISTRATION, ORAL; ANIMALS; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DRUG EVALUATION, PRECLINICAL; DYSLIPIDEMIAS; ENZYME ACTIVATION; GLUCOSE INTOLERANCE; INFLAMMATION; INSULIN RESISTANCE; LIVER; LONGEVITY; MICE; MITOCHONDRIA; MUSCLE FIBERS, SKELETAL; MUSCLES; OBESITY; OXIDATIVE STRESS; PIPERIDINES; PPAR ALPHA; RECEPTORS, ADIPONECTIN; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

MUS; RODENTIA;

EID: 84888639952     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature12656     Document Type: Article

References (43)

1. Gesta, S., Tseng, Y. H. &Kahn, C. R. Developmental origin of fat: tracking obesity to its source. Cell 131, 242-256 (2007).
2. Olefsky, J. M. &Glass, C. K. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 72, 219-246 (2010).
3. Osler, M. E. &Zierath, J. R. Adenosine 59-monophosphate-activated protein kinase regulation of fatty acid oxidation in skeletal muscle. Endocrinology 149, 935-941 (2008).
4. LeRoith, D. &Accili, D. Mechanisms of disease: using genetically altered mice to study concepts of type2diabetes. Nature Clin. Pract. Endocrinol. Metab. 4, 164-172 (2008).
5. Scherer, P. E., Williams, S., Fogliano, M., Baldini, G. &Lodish, H. F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem. 270, 26746-26749 (1995).
6. Hu, E., Liang, P. &Spiegelman, B. M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem. 271, 10697-10703 (1996).
7. Maeda, K. et al. cDNA cloning and expression of a novel adipose specific collagenlike factor, apM1 (AdiPose most abundant gene transcript 1). Biochem. Biophys. Res. Commun. 221, 286-289 (1996).
8. Nakano, Y., Tobe, T., Choi-Miura, N. H., Mazda, T. &Tomita, M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J. Biochem. 120, 803-812 (1996).
9. Hotta, K. et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol. 20, 1595-1599 (2000).
10. Yamauchi, T. et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Med. 7, 941-946 (2001).
11. Berg, A. H., Combs, T. P., Du, X., Brownlee, M. &Scherer, P. E. The adipocytesecreted protein Acrp30 enhances hepatic insulin action. Nature Med. 7, 947-953 (2001).
12. Fruebis, J. et al. Proteolytic cleavage product of 30-kDa adipocyte complementrelated protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl Acad. Sci. USA 98, 2005-2010 (2001).
13. Yamauchi, T. et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature Med. 8, 1288-1295 (2002).
14. Tomas, E. et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc. Natl Acad. Sci. USA 99, 16309-16313 (2002).
15. Kahn, B. B., Alquier, T., Carling, D. &Hardie, D. G. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 1, 15-25 (2005).
16. Kersten, S., Desvergne, B. &Wahli, W. Roles of PPARs in health and disease. Nature 405, 421-424 (2000).
17. Yamauchi, T. et al. Globular adiponectin protected ob/ob mice from diabetes and apoE deficient mice from atherosclerosis. J. Biol. Chem. 278, 2461-2468 (2003).
18. Yamauchi, T. et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423, 762-769 (2003).
19. Wess, J. G-protein-coupled receptors:molecularmechanismsinvolved in receptor activation and selectivity of G-protein recognition. FASEB J. 11, 346-354 (1997).
20. Yamauchi, T. et al. TargeteddisruptionofAdipoR1and AdipoR2causes abrogation of adiponectin binding and metabolic actions. Nature Med. 13, 332-339 (2007).
21. Iwabu, M. et al. Adiponectin and AdipoR1 regulate PGC-1a and mitochondria by Ca21 and AMPK/SIRT1. Nature 464, 1313-1319 (2010).
22. Richter, E. A. &Ruderman, N. B. AMPK and the biochemistry of exercise: implications for human health and disease. Biochem. J. 418, 261-275 (2009).
23. Wu, Z. et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98, 115-124 (1999).
24. Handschin, C. &Spiegelman, B. M. The role of exercise andPGC1a in inflammation and chronic disease. Nature 454, 463-469 (2008).
25. Cantó, C. et al. AMPK regulates energy expenditure by modulating NAD1 metabolism and SIRT1 activity. Nature 458, 1056-1060 (2009).
26. Paffenbarger, R. S. Jr et al. The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. N. Engl. J. Med. 328, 538-545 (1993).
27. Open Innovation Center for Drug Discovery. http://www. ocdd. u-tokyo. ac. jp/ library-e. html (The University of Tokyo, 2012).
28. Hawley, S. A. et al. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J. Biol. Chem. 271, 27879-27887 (1996).
29. Mootha, V. K. et al. Erra and Gabpa/b specify PGC-1a-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle. Proc. Natl Acad. Sci. USA 101, 6570-6575 (2004).
30. Berchtold, M. W. et al. Calcium ion in skeletal muscle: its crucial role for muscle function, plasticity, and disease. Physiol. Rev. 80, 1215-1265 (2000).
31. Shulman, G. I. Cellular mechanisms of insulin resistance. J. Clin. Invest. 106, 171-176 (2000).
32. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-820 (2001).
33. Lochhead, P. A. et al. 5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes 49, 896-903 (2000).
34. Hotamisligil, G. S., Shargill, N. S. &Spiegelman, B. M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259, 87-91 (1993).
35. Wellen, K. E. &Hotamisligil, G. S. Inflammation, stress, and diabetes. J. Clin. Invest. 115, 1111-1119 (2005).
36. Weisberg, S. P. et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112, 1796-1808 (2003).
37. Xu, H. et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112, 1821-1830 (2003).
38. Lumeng, C. N., Bodzin, J. L. &Saltiel, A. R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 117, 175-184 (2007).
39. Zhang, H. M. et al. Geldanamycin derivativeameliorates high fat diet-induced renal failure in diabetes. PLoS ONE 7, e32746 (2012).
40. Li, S., Shin, H. J., Ding, E. L. &van Dam, R. M. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. J. Am. Med. Assoc. 302, 179-188 (2009).
41. Pischon, T. et al. Plasma adiponectin levels and risk of myocardial infarction in men. J. Am. Med. Assoc. 291, 1730-1737 (2004).
42. Pajvani, U. B. et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J. Biol. Chem. 279, 12152-12162 (2004).
43. Luo, Z., Saha, A. K., Xiang, X. &Ruderman, N. B. AMPK, themetabolic syndromeand cancer. Trends Pharmacol. Sci. 26, 69-76 (2005).